Teva Pharmaceutical Industries Ltd (ADR) logo Jefferies Group restated their buy rating on shares of Teva Pharmaceutical Industries Ltd (ADR) (NASDAQ:TEVA) in a report released on Thursday, Analyst Ratings Net reports. Jefferies Group currently has a $61.00 price objective on the stock. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) net profit margin is 6.80% and weekly performance is -1.22%. On last trading day company shares ended up $49.25. Analysts mean target price for the company is $56.27. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) distance from 50-day simple moving average (SMA50) is -1.86%.
GlaxoSmithKline plc (ADR) (NYSE:GSK), the U.K. based biggest drug-maker expressed its happiness after the company remained as ‘interested observer’. The CEO, Andrew Witty, said that it was a joyous moment for the company, not to directly involve with the rivalry AstraZeneca Plc on the basis of the potential sale. GlaxoSmithKline plc (ADR) (NYSE:GSK) shares advanced 0.16% in last trading session and ended the day on $54.99. GSK gross Margin is 69.60% and its return on assets is 17.30%.GlaxoSmithKline plc (ADR) (NYSE:GSK) quarterly performance is 5.47%.
Swiss drug maker Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) reported a 1% dip in first-quarter revenue as the strong Swiss franc eroded the value of growing sales of its cancer drugs. In the quarter ending March 31, Roche said its overall group sales fell to 11.496 billion Swiss francs ($13.06 billion), edging out the 11.49 billion francs analysts had forecast. Excluding the currency impact, sales rose 5%. Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) shares moved up 0.80% in last trading session and was closed at $36.10, while trading in range of $35.83 – $36.19.
Germany’s Bayer AG (ADR) (OTCMKTS:BAYRY) plans to buy U.S.-based Merck & Co.’s consumer health business, creating a combined medicine cabinet of household names from Bayer’s aspirin to Merck’s Claritin allergy pills. Bayer AG (ADR) (OTCMKTS:BAYRY) ended the last trading day at $138.39.
Syngenta AG (ADR) (NYSE:SYT) said it will start a second African seed-treatment institute in Kenya in 2016 and plans to expand in the continent’s western nations in the next five years. The company opened its first research and development facility on the continent in the South African town of Brits this week and plans another in Kenya in two years, said Abraham Vermeulen, the company’s head of corn, sugar and diverse field crops in the region. The Brits unit is Basel-based Syngenta’s 11th such plant and it plans to have a total of 18 centres by the end of 2016, he said. Syngenta AG (ADR) (NYSE:SYT) ended the last trading day at $77.89. Company weekly volatility is calculated as 0.66% and price to cash ratio as 40.53.Syngenta AG (ADR) (NYSE:SYT) showed a positive weekly performance of 0.70%.